SEC and FDA Announce MOU to Bolster Cooperation and Ensure Market Integrity

The Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have signed a Memorandum of Understanding (MOU) to strengthen cooperation and ensure market integrity. The MOU aims to support both agencies in carrying out their missions of maintaining the integrity of financial markets and safeguarding public health. By establishing a framework for enhanced cooperation in regulatory and enforcement responsibilities, the MOU aims to improve market oversight and compliance.

Among the key provisions of the MOU are information-sharing protocols that facilitate the exchange of relevant information between the SEC and FDA. These protocols will help both agencies work together more effectively in their critical missions. SEC Chairman Paul S. Atkins emphasized the significant impact FDA-related disclosures by public companies have on the markets, stating that the FDA is a valuable partner in administering and enforcing disclosure requirements under federal securities laws. He looks forward to strengthening the partnership through the MOU.

Acting FDA Commissioner Kyle Diamantras J.D. expressed pride in the partnership with the SEC, highlighting the importance of streamlining information-sharing to protect patients who rely on FDA-regulated products and maintain public trust in healthcare innovation. The MOU will remain in effect for three years and can be extended or modified with mutual written consent of the agencies.